Core Insights - HydroGraph Inc. is collaborating with Hawkeye Bio and Ease Healthcare to commercialize a new lung cancer screening product called LEAP, which utilizes HydroGraph's patented fractal graphene technology [1][2][4] - The LEAP test is a non-invasive blood test with a 99.8% negative predictive value, aimed at early detection of lung cancer in high-risk populations [2][5] - The partnership highlights the medical potential of high-purity graphene in diagnostics, with HydroGraph's technology supporting innovative solutions for cancer detection [4][5] Company Overview - HydroGraph is a leading producer of ultra-pure graphene using an "explosion synthesis" process, ensuring exceptional purity and consistency [8] - Hawkeye Bio specializes in developing low-cost diagnostic tests for early detection of cancer and other diseases, with a focus on using nanoscale graphene biosensors [7][8] - Ease Healthcare is responsible for marketing the LEAP test, which is designed to be a cost-effective diagnostic solution for primary care physicians [5][10] Market Context - Lung cancer is the leading cause of cancer deaths in the U.S., with an estimated 125,000 deaths and 227,000 new cases expected in 2025 [4] - Current screening compliance is low, with only 2% to 6% of at-risk individuals undergoing recommended screenings, despite the benefits of early detection [4] - The eligible population for lung cancer screening in the U.S. is currently estimated at 15-19.3 million, with expectations for growth as screening guidelines evolve [6]